Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3650-3656

  Hubert, Dominique ^a   Le Roux, Evelyne ^b   Lavrut, Thibaud ^c   Wallaert, Benoit ^d   Scheid, Philippe ^e   Manach, Dominique ^a   Grenet, Dominique ^f   Sermet Gaudelus, Isabelle ^g   Ramel, Sophie ^h   Cracowski, Claire ⁱ   Sardet, Anne ^j   Wizla, Nathalie ^d   Deneuville, Eric ^k   Garraffo, Rodolphe ^c  

^a Hôpital Cochin ^*  (France)

^b Vaincre la Mucoviscidose   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CHU NANCY BRABOIS   (France)

^f FOCH HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Centre de Perharidy   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j Centre Hospitalier de LENS   (France)

^k SERVICE DE RHUMATOLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; TOBRAMYCIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG TOLERANCE; EXPIRATORY RESERVE VOLUME; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEMOPTYSIS; HUMAN; LEUKOCYTE COUNT; LOADING DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 70349155467     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00174-09     Document Type: Article

References (33)

1. Alou, L., L. Aguilar, D. Sevillano, M. J. Giménez, O. Echeverría, M. L. Gómez-Lus, and J. Prieto. 2005. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J. Antimicrob. Chemother. 55:209-213. (Pubitemid 40331147)
2. Baririan, N., H. Chanteux, E. Viaene, H. Servais, and P. M. Tulkens. 2003. Stability and comparability study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J. Antimicrob. Chemother. 51:651-658.
3. Benko, A. S., D. M. Cappelletty, J. A. Kruse, and M. J. Rybak. 1996. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob. Agents Chemother. 40:691-695.
4. Bosso, J. A., C. R. Bonapac, P. A. Flume, and R. L. White. 1999. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 19:620-626.
5. Byl, B., D. Baran, F. Jacobs, A. Herschuelz, and J. P. Thys. 2001. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J. Antimicrob. Chemother. 48:325-327.
6. Cystic Fibrosis Foundation. 2007. Patient registry 2006. Annual data report to the centers directors. Cystic Fibrosis Foundation, Bethesda, MD.
7. Daenen, S., Z. Erjavec, D. R. A. Uges, H. G. De Vries-Hospers, P. De Jonge, and M. R. Halie. 1995. Continuous infusion of ceftazidime in febrile neutropenic patients in acute myeloid leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 14:188-192.
8. David, T. J., and J. Devlin. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lancet i:1454-1455. (Pubitemid 19150076)
9. Döring, G., J. S. Elborn, M. Johannesson, H. de Jonge, M. Griese, A. Smyth, and H. Heijerman for the Consensus Study Group. 2007. Clinical trials in cystic fibrosis. J. Cyst. Fibros. 6:85-99.
10. Fuchs, H. J., D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey, B. J. Rosenstein, A. L. Smith, and M. E. Wohl. 1994. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 331:637-642.
11. Henry, B., P. Aussage, C. Grosskopf, and J. M. Goehrs. 2003. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual. Life Res. 12:63-76.
12. Jehl, F., P. Birckel, and H. Monteil. 1987. Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography. J. Chromatogr. 413:109-119. (Pubitemid 17004998)
13. Kuzemko, J., and C. Crawford. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lancet ii:385. (Pubitemid 19189086)
14. Lipman, J., C. D. Gomersall, T. Gin, G. M. Joynt, and R. J. Young. 1999. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J. Antimicrob. Chemother. 43:309-311.
15. MacGowan, A. P., and K. E. Bowker. 1998. Continuous infusion of β-lactam antibiotics. Clin. Pharmacokinet. 35:391-402.
16. Manduru, M., L. B. Mihm, R. L. White, L. V. Friedrich, P. A. Flume, and J. A. Bosso. 1997. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates derived from cystic fibrosis patients. Antimicrob. Agents Chemother. 41:2053-2056.
17. Mouton, J. W., and A. A. Vinks. 1996. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J. Antimicrob. Chemother. 38:5-15.
18. Nicolau, D. P., C. H. Nightingale, M. A. Banevicius, Q. Fu, and R. Quintiliani. 1996. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob. Agents Chemother. 40:61-64.
19. Pea, F., P. Viale, D. Damiani, F. Pavan, F. Cristini, R. Fanin, and M. Furlanut. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob. Agents Chemother. 49:3350-3353.
20. Pitt, T. L., M. Sparrow, M. Warner, and M. Stefanidou. 2003. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58:794-796.
21. Plasse, J. C., C. Chabloz, A. Terrier, and G. Bellon. 2002. Is it safe to administer a continuous infusion of ceftazidime (Fortum®) prepared for 24 hours in cystic fibrosis patients? Pediatr. Pulmonol. 33:232-233.
22. Rappaz, I., L. A. Decosterd, J. Bille, M. Pilet, N. Bélaz, and M. Roulet. 2000. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur. J. Pediatr. 159:919-923.
23. Riethmüller, J., A. Busch, P. Franke, R. Ziebach, R. von Butler, and M. Stern. 2000. Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF patients is equally effective, abstr. 340. Abstr. 13th Eur. Cystic Fibrosis Conf.
24. Sanders, D. B., M. Rosenfeld, N. Mayer-Hamblett, D. Stamey, and G. J. Redding. 2007. Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations. Pediatr. Pulmonol 43:1142-1146.
25. Smith, A. L., S. B. Fiel, N. Mayer-Hamblett, B. Ramsey, and J. L. Burns. 2003. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis. Chest 123:1495-1502.
26. Smyth, A., K. H. V. Tan, P. Hyman-Taylor, M. Mulheran, S. Lewis, D. Stableforth, and A. Knox. 2005. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 365:573-578. (Pubitemid 40247913)
27. Société Française de Microbiologie. 2003. Report 2003 of the Antibiogramme Committee of the French Society for Microbiology. Société Française de Microbiologie, Paris, France. http://www.sfm.asso.fr.
28. Spino, M. 1991. Pharmacokinetics of drugs in cystic fibrosis. Clin. Rev. Allergy 9:169-210.
29. Touw, D. J., A. A. Vinks, J. W. Mouton, and A. M. Horrevorts. 1998. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestion for future directions. Clin. Pharmacokinet. 35:437-459.
30. Viaene, E., H. Chanteux, H. Servais, M.P. Mingeot-Leclercq, and P. Tulkens. 2002. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46:2327-2332. (Pubitemid 34793431)
31. Vic, P., S. Ategbo, D. Turck, M. O. Husson, V. Launay, G. A. Loeuille, A. Sardet, A. Deschildre, D. Druon, and C. Arrouet-Lagande. 1998. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch. Dis. Child. 78:536-539.
32. Vinks, A. A., D. J. Touw, H. G. Heijerman, M. Danhof, G. P. de Leede, and W. Bakker. 1994. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther. Drug Monit. 16:341-348.
33. Vinks, A. A., R. W. Brimicombe, H. G. Heijerman, and W. Bakker. 1997. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother. 40:125-133.